Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia

Leukemia

Volumn 11, Issue 4, 1997, Pages 581-587

  Lewis, I D ^a   Haylock, D N ^a   Moore, S ^a   To, L B ^a   Hughes, T P ^a  

^a HANSON INSTITUTE   (Australia)

Author keywords

Blood; CML; Normal; Phenotype; Pre progenitors

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; HLA DR ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; APHERESIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

EID: 0030986153     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400604     Document Type: Article

References (21)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
2. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-214.
3. McGlave P. Bone marrow transplants in chronic myelogenous leukemia: An overview of determinants of survival. Semin Hematol 1990; 27(4 Suppl. 3): 23-30.
4. Butturini A, Keating A, Goldman J, Gale RP. Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 1990; 335: 1255-1258.
5. Goto T, Nishikori M, Arlin Z, Gee T, Kempin S, Burchenal J, Strife A, Wisniewski D, Lambek C, Little C, Jhanwar S, Chaganti R, Clarkson B. Growth characteristics of leukemic and normal hematopoietic cells in Ph+ chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793-808.
6. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532-538.
7. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. New Engl J Med 1983; 308: 1493-1498.
8. Verfaillie CM, Miller WJ, Boylan K, McGalve PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
9. Leemhuis T, Leibowitz D, Cox C, Silver R, Srour EF, Tricot G, Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 81: 801-807.
10. Moore MAS. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 1991; 78: 1-19.
11. - progenitor cells. Blood 1991; 77: 1218-1227.
12. Iscove NN, Shaw AR, Keller G. Net increase of pluripotential hematopoietic precursors in suspension culture in response to IL-1 and IL-3. J Immunol 1989; 142: 2332-2337.
13. Cross NCP, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67-74.
14. lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization. Blood 1995; 86: 737-743.
15. De Fabritiis P, Dowding C, Bungey J, Chase A, Angus G, Szydlo R, Goldman JM. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells. Leuk Lymphoma 1993; 11: 51-61.
16. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D. Autologous transplants for chronic myeloid leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
17. De Fabritiis P, Amadori S, Calabretta B, Mandelli F. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligonucleotides. Bone Marrow Transplant 1993; 12: 261-265.
18. Turhan AC, Humphries RK, Eaves CJ, Barnett MJ, Phillips GL, Kalousek DK, Klingemnann HG, Lansdorp PL, Reece DE, Shepherd JD, Eaves AC. Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood 1990; 76: 2404-2410.
19. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
20. Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, Przepiorka D, Van Besien K, Andersson B, Mehra R, Gajewski J, Seong D, Hester J, Estey E, Korbling M, Pollicardo N, Berenson R, Heimfeld S, Champlin R, Deisseroth AB. Percentage of Philadelphia chromosome(Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 1995; 85: 3257-3263.
21. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Devvald G, Heimfeld S, Miller JS, McGlave P. BCR/ABL negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87: 4770-4779.